Clinical Implications of APOBEC3-Mediated Mutagenesis in Breast Cancer.
Clinical Implications of APOBEC3-Mediated Mutagenesis in Breast Cancer.
复制标题
DOI：
10.1158/1078-0432.ccr-22-2861
复制
发表时间：
2023-05-01
影响因子：
11.5
通讯作者：
Span, Paul N.
中科院分区：
文献类型：
--
作者：
Roelofs, Pieter A.;Martens, John W. M.;Harris, Reuben S.;Span, Paul N.
近年来，胞嘧啶脱氨酶的APOBEC3家族的成员已经涉及增加的癌症基因组诱变，从而导致肿瘤内和肿瘤间基因组异质性和尤其是乳腺癌的治疗抗性。了解这些酶的临床检测可用的方法，其（失调）表达所需的条件，它们的临床影响以及它们可能提供的临床意义对于了解APOBEC3介导的突变在乳腺癌中的当前影响至关重要。在这里，我们提供了一个全面的审查APOBEC3介导的诱变和负责APOBEC3酶的检测的最新进展，总结控制其表达的途径，并探讨其临床后果和机会。我们认为，APOBEC3介导的突变可以作为一个有用的预测生物标志物在几个标准的护理乳腺癌治疗计划，并可能是一个新的治疗目标。
Over recent years, members of the APOBEC3 family of cytosine deaminases have been implicated in increased cancer genome mutagenesis, thereby contributing to intra- and inter-tumor genomic heterogeneity and therapy resistance in, amongst others, breast cancer. Understanding the available methods for clinical detection of these enzymes, the conditions required for their (dysregulated) expression, the clinical impact they have, and the clinical implications they may offer is crucial in understanding the current impact of APOBEC3-mediated mutagenesis in breast cancer. Here, we provide a comprehensive review of recent developments in the detection of APOBEC3-mediated mutagenesis and responsible APOBEC3 enzymes, summarize the pathways that control their expression, and explore the clinical ramifications and opportunities they pose. We propose that APOBEC3-mediated mutagenesis can function as a helpful predictive biomarker in several standard-of-care breast cancer treatment plans and may be a novel target for treatment.
影响因子：
4.6
作者：
Shi K;Demir Ö;Carpenter MA;Wagner J;Kurahashi K;Harris RS;Amaro RE;Aihara H
通讯作者：
Aihara H
DOI：
10.3390/v13020290
发表时间：
2021-02-12
期刊：
Viruses
影响因子：
--
作者：
Barzak FM;Ryan TM;Kvach MV;Kurup HM;Aihara H;Harris RS;Filichev VV;Harjes E;Jameson GB
通讯作者：
Jameson GB
影响因子：
2
作者：
Saito Y;Miura H;Takahashi N;Kuwahara Y;Yamamoto Y;Fukumoto M;Yamamoto F
通讯作者：
Yamamoto F